The Cancer and Leukemia Group B Pathology Committee at 50
Open Access
- 1 June 2006
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (11) , 3617s-3621s
Abstract
The Pathology Committee of the Cancer and Leukemia Group B (CALGB) is broadly and deeply integrated into the multidisciplinary clinical and scientific operations of the group. It has five major functions in CALGB. First, it insures the highest possible quality of pathologic data in tissue-based correlative science studies through comprehensive quality control of all tissues collected, banked, and distributed to investigators and of all morphology-based studies done within the CALGB. Within this context, the Pathology Committee has the goal of eliminating, to the greatest degree possible, variation in methodology, interpretation, and reporting of pathologic data that would compromise reproducibility of correlative science results and to assure accuracy, uniformity, and completeness of the pathologic data. Second, the committee provides expert pathologic consultation in the development of clinical trials and correlative science studies that involve pathologic issues and/or materials. Third, it provides high-quality tissue banking and centralized morphology-based technical support services (e.g., histologic sections for immunohistochemistry, tissue microarrays, etc.) for all CALGB investigators. Fourth, it initiates and executes high-quality pathologic research using CALGB and intergroup resources. Lastly, it provides group-wide education on pathology-related issues relevant to trial design, scientific study design, and specimen banking.Keywords
This publication has 48 references indexed in Scilit:
- Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer PatientsJournal of Clinical Oncology, 2005
- Sentinel Node Staging of Resectable Colon CancerAnnals of Surgery, 2004
- Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancersInternational Journal of Cancer, 2004
- Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphomaCancer, 2004
- Immunoreactivity of MIC2 (CD99) in Acute Myelogenous Leukemia and Related DiseasesLaboratory Investigation, 2000
- Flow cytometry in node‐positive breast cancer: Cancer and leukemia group B protocol 8869Cytometry, 1995
- Morphologic characteristics of erythroleukemia (Acute Myeloid Leukemia; FAB‐M6): A CALGB studyAmerican Journal of Hematology, 1995
- Combination trial of subcutaneous recombinant α2b interferon and oral cyclophosphamide in follicular low‐grade non‐Hodgkin's lymphomaMedical and Pediatric Oncology, 1994
- Morphologic and cytochemical characteristics of acute promyelocytic leukemiaAmerican Journal of Hematology, 1989
- Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: Relationship to response to remission induction therapyEuropean Journal of Cancer and Clinical Oncology, 1985